title: [Insulin degludec--a new basal insulin for the treatment of type 1 and type 2 diabetes].
abstract: After subcutaneous injection, IDeg self-associates to form multihexamer chains that slowly dissociate into monomers. This results in a duration of action of more than 42 hours as well as a smooth level action profile with low intra-individual variability. Pharmacokinetic studies foun IDeg to have a half-life of approximately 25 hours which is considerably longer than that from other current insulin formulations. Based on these properties, IDeg demonstrated low risk for nocturnal hypoglycaemic events in the clinical study program. Concurrently, phase 3 studies have provided evidence for a non-inferior glucose lowering effect when compared to other currently available basal insulin formulations. Moreover, the long duration of action suggests a flexible handling which could be better adapted to patients' needs in daily routine. This article gives an overview of the mechanism of action of IDeg and the latest results from phase 2 and phase 3 studies.
authors.forename: B
authors.initials: B
authors.lastname: Gallwitz
authors.forename: T
authors.initials: T
authors.lastname: Haak
mesh_terms: D001682:Biological Availability; D001786:Blood Glucose / Q000378:metabolism; D017326:Clinical Trials, Phase III as Topic; D003692:Delayed-Action Preparations; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000188:drug therapy*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D004334:Drug Administration Schedule; D006207:Half-Life; D006801:Humans; D007279:Injections, Subcutaneous; D049528:Insulin, Long-Acting / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*
chemical_list: D001786:Blood Glucose; D003692:Delayed-Action Preparations; D049528:Insulin, Long-Acting; C571886:insulin degludec